|
|
| | Methylglucamine antimonate Basic information |
| Product Name: | Methylglucamine antimonate | | Synonyms: | 1-deoxy-1-(methylamino)-,compd.withantimonicacid(1:1),d-glucito;1-deoxy-1-(methylamino)-d-glucitocompd.withantimonicacid(1:1);1-deoxy-1-(methylamino)-d-glucitotrioxoantimonate(1-);2168-rp;glucantime;meglumineantimonate;methylglucamineantimonate;protostib | | CAS: | 133-51-7 | | MF: | C7H18NO8Sb | | MW: | 365.98 | | EINECS: | 205-108-3 | | Product Categories: | | | Mol File: | 133-51-7.mol |  |
| | Methylglucamine antimonate Chemical Properties |
| storage temp. | Refrigerator, Under inert atmosphere | | solubility | Acidic DMSO (Slightly, Sonicated), Aqueous Base (Very Slightly, Heated) | | form | Solid | | color | White to Off-White | | CAS DataBase Reference | 133-51-7(CAS DataBase Reference) | | EPA Substance Registry System | Glucantime (133-51-7) |
| | Methylglucamine antimonate Usage And Synthesis |
| Uses | In the synthesis of surface active agents, pharmaceuticals, dyes. | | Pharmaceutical Applications | N-Methylglucamine antimonate; methylaminoglucitol antimonate.
The SbV content varies around 28% between batches.
The major moieties are SbV–ligand complexes which are zwitterionic
in solution.
The activity, pharmacology and toxicology are similar to
those of sodium stibogluconate, with which it is essentially
interchangeable. | | Clinical Use | Treatment of visceral and cutaneous leishmaniasis
Studies in Central and South America have indicated that the
combination with interferon-γ is effective in the treatment of
visceral and cutaneous leishmaniasis cases unresponsive to
antimony alone. |
| | Methylglucamine antimonate Preparation Products And Raw materials |
|